Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever This table compares Atyr PHARMA and CG Oncology’s net margins, return on ...

Efzofitimod is under clinical development by aTyr Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

If you want to know who really controls aTyr Pharma, Inc. (NASDAQ:ATYR), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

aTyr Pharma, Inc. announced the appointment of Eric Benevich to its Board of Directors, effective December 10, 2024. Benevich, currently the Chief Commercial Officer at Neurocrine Biosciences ...

aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company, is garnering attention from investors and analysts alike as it advances its lead candidate, efzofitimod, through late-stage ...

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on aTyr Pharma (ATYR – Research Report). The associated price target remains the same with $22.00. Pick the best stocks and ...